SOLENO THERAPEUT. DL-001 (6XC) - Total Assets
Based on the latest financial reports, SOLENO THERAPEUT. DL-001 (6XC) holds total assets worth €563.83 Million EUR (≈ $659.18 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is SOLENO THERAPEUT. DL-001's book value for net asset value and shareholders' equity analysis.
SOLENO THERAPEUT. DL-001 - Total Assets Trend (2021–2025)
This chart illustrates how SOLENO THERAPEUT. DL-001's total assets have evolved over time, based on quarterly financial data.
SOLENO THERAPEUT. DL-001 - Asset Composition Analysis
Current Asset Composition (December 2025)
SOLENO THERAPEUT. DL-001's total assets of €563.83 Million consist of 63.1% current assets and 36.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.4% |
| Accounts Receivable | €28.21 Million | 5.0% |
| Inventory | €15.02 Million | 2.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.86 Million | 0.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SOLENO THERAPEUT. DL-001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SOLENO THERAPEUT. DL-001 stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SOLENO THERAPEUT. DL-001's current assets represent 63.1% of total assets in 2025, an increase from 63.1% in 2021.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, down from 59.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 35.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 5.0% of total assets.
SOLENO THERAPEUT. DL-001 Competitors by Total Assets
Key competitors of SOLENO THERAPEUT. DL-001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
SOLENO THERAPEUT. DL-001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.80 | 15.68 | 17.26 |
| Quick Ratio | 5.55 | 15.68 | 17.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €294.45 Million | €275.14 Million | €243.24 Million |
SOLENO THERAPEUT. DL-001 - Advanced Valuation Insights
This section examines the relationship between SOLENO THERAPEUT. DL-001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.57 |
| Latest Market Cap to Assets Ratio | 4.09 |
| Asset Growth Rate (YoY) | 70.4% |
| Total Assets | €563.83 Million |
| Market Capitalization | $2.31 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values SOLENO THERAPEUT. DL-001's assets at a significant premium (4.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: SOLENO THERAPEUT. DL-001's assets grew by 70.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SOLENO THERAPEUT. DL-001 (2021–2025)
The table below shows the annual total assets of SOLENO THERAPEUT. DL-001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €563.83 Million ≈ $659.18 Million |
+70.36% |
| 2024-12-31 | €330.97 Million ≈ $386.94 Million |
+83.17% |
| 2023-12-31 | €180.69 Million ≈ $211.25 Million |
+581.93% |
| 2022-12-31 | €26.50 Million ≈ $30.98 Million |
-25.47% |
| 2021-12-31 | €35.55 Million ≈ $41.57 Million |
-- |
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more